SEC Form 4 · accession 0001567619-18-002984
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Edward P. Feener
Officer — Chief Scientific Officer
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 7:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 18, 2018 | A | 12,500 | $0.00 | A | 110,534 | D | |
| Common StockF2 | Sep 18, 2018 | F | 2,500 | $17.05 | D | 108,034 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $16.08 | Sep 18, 2018 | A | 52,600 | A | — | Sep 17, 2028 | Common Stock | 52,600 | 52,600 | D |
Explanation of responses
- F1Represents the number of shares vested upon the achievement of certain performance criteria pursuant to a performance based restricted stock units ("PSUs") granted by the Issuer's Compensation Committee in June 2018. No sale or disposition of these shares is contemplated until after the expiration of the applicable lock-up period.
- F2Represents the number of shares of common stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent a sale by the reporting person.
- F3The option vests over a 4 year period: 1/48th on October 18, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.